New research suggests that people who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who stop traditional diet and exercise programs.
Published data in a major medical journal shows that while obese individuals often shed a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Users buying such treatments need to be aware of the potential of fast weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment mass in about 18 months.
Comparing Treatments
The study, which looked at dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
The team point out that individuals who lose weight through diet and exercise usually see a more gradual weight regain—around 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Doctors suggest the way of the drugs is key to understanding the amplified rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the system to produce less of its own natural hormone, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
The NHS recommend the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts contend that, considering the high risk of weight regain, the treatment is often long-term.
This opinion is reinforced by drug manufacturers, who say that the results "emphasize the chronic character of excess weight," similar to managing diseases like diabetes.
User Testimonies
People who have stopped the jabs report a sudden resurgence of cravings.
"I experienced a switch that goes on and you become extremely hungry," described an individual.
This difficulty is compounded if users have not developed permanent lifestyle or habit changes during treatment.
Significant Interest
Recent estimates show that millions of adults in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while these medications are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated behavioural management.
